Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, pharmacokinetics, and pharmacodynamics study of intravenous GH002 in healthy volunteers
NL-OMON53619Phase 1Completed
- Sponsor
- GH Research PLC
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in treatment-resistant depression (TRD) comparing GH002 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics of 5-MeO-DMT. Started Jan 2023; status: completed.
02
Drugs
5-MeO-DMT
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON53619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53619.